Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein - PubMed (original) (raw)

. 2009 Dec;10(6):499-506.

doi: 10.1016/j.cmet.2009.10.007.

Irena D Ignatova, Shin Yonemitsu, Yoshio Nagai, Paula Chatterjee, Dirk Weismann, Jennifer J Hsiao, Dongyan Zhang, Takanori Iwasaki, Romana Stark, Clare Flannery, Mario Kahn, Christopher M Carmean, Xing Xian Yu, Susan F Murray, Sanjay Bhanot, Brett P Monia, Gary W Cline, Varman T Samuel, Gerald I Shulman

Affiliations

Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein

Derek M Erion et al. Cell Metab. 2009 Dec.

Abstract

In patients with poorly controlled type 2 diabetes mellitus (T2DM), hepatic insulin resistance and increased gluconeogenesis contribute to fasting and postprandial hyperglycemia. Since cAMP response element-binding protein (CREB) is a key regulator of gluconeogenic gene expression, we hypothesized that decreasing hepatic CREB expression would reduce fasting hyperglycemia in rodent models of T2DM. In order to test this hypothesis, we used a CREB-specific antisense oligonucleotide (ASO) to knock down CREB expression in liver. CREB ASO treatment dramatically reduced fasting plasma glucose concentrations in ZDF rats, ob/ob mice, and an STZ-treated, high-fat-fed rat model of T2DM. Surprisingly, CREB ASO treatment also decreased plasma cholesterol and triglyceride concentrations, as well as hepatic triglyceride content, due to decreases in hepatic lipogenesis. These results suggest that CREB is an attractive therapeutic target for correcting both hepatic insulin resistance and dyslipidemia associated with nonalcoholic fatty liver disease (NAFLD) and T2DM.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Xing Xian Yu, Susan F. Murray, Sanjay Bhanot, and Brett P. Monia own stock and/or hold stock options in Isis Pharmaceuticals.

Figures

Figure 1

Figure 1. CREB ASO improves metabolic parameters in three other diabetic models

Fasting plasma glucose (A), and insulin (B) concentrations (n = 8–21) in the T2DM rat model. Fasting plasma glucose concentrations (C) were decreased with CREB ASO in the ZDF rat model (n = 4–5). Due to the pancreas saving effect of lower glucose values plasma insulin values tended to be increased (D) (n = 4–5). In the lard diet based model, CREB ASO reduced fasting plasma glucose (E), and insulin (F) concentrations (n = 7–9). Lastly, CREB ASO also reduced fasting plasma glucose in an ob/ob mouse model (G) due to reductions in gluconeogenic genes (H) (n = 4–5). * P < 0.05, ** P < 0.005.

Figure 2

Figure 2. CREB ASO treatment reduces hepatic lipid content

Long chain acyl CoAs (A), and liver DAGs (B) were decreased with CREB ASO treatment (n = 8–10). Liver triglycerides were reduced in the fasted and fed states with CREB ASO (C). In-vivo lipogenesis was reduced with CREB ASO as assessed by the incorporation of [1-14C]-palmitate in to triglycerides (n = 4 per group) (D). C/EBPα (E), C/EBPβ (F), and key lipogenic genes (G) assessed by RT-PCR (n = 4–7). * P < 0.05, ** P < 0.005 for Control ASO vs. CREB ASO, # P < 0.05 for control ASO fasted vs. control ASO fed.

Figure 3

Figure 3. CREB ASO treatment improves hepatic insulin sensitivity in T2DM Rats

Suppression of hepatic glucose production (A) was assessed using the hyperinsulinemic-euglycemic clamp (n = 4–14 per treatment group). In the T2DM rat model CREB ASO reduced membrane PKCε (B) (n = 4 per treatment group), increased IRS-2 tyrosine phosphorylation (C) (n = 9 per treatment group), and improved Akt2 activity (D) (n = 5 per treatment group). * P < 0.05 for CREB ASO vs. control ASO, # P < 0.05 for T2DM control ASO vs. normal chow control ASO.

Figure 4

Figure 4. CREB ASO therapy decreases plasma triglycerides and cholesterol

Plasma triglycerides were decreased with CREB ASO (n = 10–12) (A). The lipoprotein profile showed significant reductions in VLDL, LDL, and HDL with CREB ASO (B). Free hepatic cholesterol was unchanged with CREB ASO (n = 4 per treatment group) (C) but CREB ASO decreased the concentration of hepatic cholesterol esters (D) as assessed by NMR. Synthesis of cholesterol in rat hepatocytes as assessed by relative [14C] acetic acid incorporation in to sterols (E) (n = 3–7 per treatment group). Amount of bile acids extracted from feces during a 12 hour fast (G) (n = 7 per treatment group). * P < 0.05 for control ASO vs. CREB ASO.

Similar articles

Cited by

References

    1. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917. - PubMed
    1. Canettieri G, Koo SH, Berdeaux R, Heredia J, Hedrick S, Zhang X, Montminy M. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab. 2005;2:331–338. - PubMed
    1. Cherrington AD, Stevenson RW, Steiner KE, Davis MA, Myers SR, Adkins BA, Abumrad NN, Williams PE. Insulin, glucagon, and glucose as regulators of hepatic glucose uptake and production in vivo. Diabetes Metab Rev. 1987;3:307–332. - PubMed
    1. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem. 2007;282:22678–22688. - PubMed
    1. Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, Iwasaki T, Stark R, Weismann D, Yu XX, et al. SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci U S A. 2009;106:11288–11293. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources